He reported no gastrointestinal effects.<h4>Conclusion</h4>The addition of a proton pump inhibitor to nonsteroidal anti-inflammatory drug therapy can reduce the risk of peptic ulcer bleeding by >/=80%, making the incidence of gastropathy the same as with cyclooxygenase-2-specific inhibitors. This evidence concerns the gene PTGS2 and peptic ulcer disease.